Children's Hospital Los Angeles Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional)

洛杉矶儿童医院（CHLA） 洛杉矶儿童医院（CHLA）提议成为洛杉矶财团的牵头机构。的 主要目标是与Westat合作，作为青少年试验网络（ATN）的运营， 合作中心（OCC）成功规划和实施ATN临床研究，以满足 SLC RFA-HD-23-020中概述的优先领域。CHLA将利用Connect to Protect的优势 洛杉矶（C2 PLA）联盟领导社区，临床和学术研究咨询委员会 合作伙伴： 1.进行ATN执行和科学领导委员会确定的研究项目; 2.利用我们的社区，学术和临床合作伙伴参与试验的开发， 与ATN科学核心相结合，以满足青少年和年轻人（AYA）的需求- 有感染艾滋病毒的风险或已感染艾滋病毒; 3.在ATN V内为成功招募和入组的创新战略做出贡献 参与者通过诊所、学术大学、社区 组织、卫生部门和其他合作伙伴; 4.为研究中心提供当地实验室能力和药房支持;以及 5.建立一个领导模式，通过有意义和持续的社区参与努力，以确保 调查研究反映了AYA在哪里获得预防和护理服务。 我们提议的联盟最初将包括九个合作伙伴，他们将把自己的优势和多样性带到一个网站上。 该联盟将包括临床、学术、政府、社区和其他合作伙伴。我们有四 为艾滋病病毒感染者和艾滋病风险患者提供护理的临床站点，主要包括有色人种的LGBTQ AYA 和两个合作伙伴，目前拥有艾滋病毒感染者和艾滋病毒风险的大型数据库：ATN CARES 在加州大学洛杉矶分校和NIDA UO 1资助的健康青年男性/跨肤色青年研究队列在CHLA。我们 最初的目标是四个社区组织和洛杉矶县政府。 艾滋病毒和性传播疾病方案公共卫生司。这些团体和我们的AYA社区的代表 咨询委员会将形成一个创新的领导结构，代表我们的社区， 通过方案审查、新方案制定和招聘指导提供领导， 潴留基于数十年的临床服务经验和AYA的研究，我们提出的洛杉矶 洛杉矶ATN V财团非常适合加入OCC和其他城市财团。CHLA拥有卓越的 在未来的临床试验中可能需要获得AYA，数十年的持续社区合作伙伴关系，以及 在招募和留住难以进入临床试验的AYA方面有着出色的记录，包括复杂的 需要研究性新药（IND）、研究实验室和药房服务的医疗干预。

ABSTRACT Children's Hospital Los Angeles (CHLA) Children's Hospital Los Angeles (CHLA) is proposing to be the lead site for the Los Angeles Consortium. The primary aim is to collaborate with Westat as the Adolescent Trials Network (ATN) Operations and Collaborations Center (OCC) to successfully plan and implement ATN clinical research studies to meet the priority areas as outlined in SLC RFA-HD-23-020. CHLA will leverage the strength of the Connect to Protect Los Angeles (C2PLA) Coalition to lead a Research Advisory Committee of community, clinical, and academic partners to: 1. Conduct the Research Projects identified by the ATN Executive and Scientific Leadership Committees; 2. Participate in the development of trials using our community, academic, and clinical partners in conjunction with the ATN Scientific Core to meet the needs of adolescents and young adults (AYA) at- risk for or living with HIV; 3. Contribute to innovative strategies within ATN V regarding successful recruitment and enrollment of participants through established collaborations among clinics, academic universities, community-based organizations, health departments, and other partners; 4. Provide sites with local laboratory capacity and pharmacy support; and 5. Establish a leadership model with meaningful and sustained community engagement efforts to ensure that research studies reflect where AYA are accessing prevention and care services. Our proposed consortium will initially include nine partners who will bring their strength and diversity to a site consortium that will include clinical, academic, government, community, and other partnerships. We have four clinical sites that provide care to AYA living with HIV and at risk for HIV including mostly LGBTQ AYA of color and two partners that currently house large databases of AYA living with HIV and at risk for HIV: ATN CARES at UCLA and the NIDA UO1-funded Healthy Young Men/A Trans Youth of Color Study cohort at CHLA. We have initially targeted four community-based organizations and the County of Los Angeles Department of Public Health Division of HIV and STD Programs. Representatives of these groups and our AYA community advisory boards will form an innovative leadership structure that is representative of our communities and can provide leadership through protocol review, new protocol development, and guidance on recruitment and retention. Based on decades of experience with clinical services and research with AYA, our proposed Los Angeles ATN V Consortium is well suited to join the OCC and other city consortia. CHLA has exceptional access to AYA likely needed in future clinical trials, decades of ongoing community partnerships, and an outstanding track record for recruiting and retaining hard to reach AYA into clinical trials, including complex medical interventions requiring investigational new drugs (IND), research laboratories, and pharmacy services.